Proteomic analysis of the cerebrospinal fluid in Alzheimer’s disease Proteomska analiza cerebrospinalne tekućine u Alzheimerovoj bolesti Prof. dr. sc.

Slides:



Advertisements
Similar presentations
Mild cognitive impairment (MCI) is a syndrome characterized by cognitive impairment without dementia, which primarily affects episodic memory. Patients.
Advertisements

This teaching material has been made freely available by the KEMRI-Wellcome Trust (Kilifi, Kenya). You can freely download, adapt, and distribute this.
Results All neuropathologies were associated with clinical dementia when controlling for cortical plaques and tangles except Hirano bodies, GVD and brainstem.
AD Research Update Steven H. Ferris, PhD Friedman Professor and Director NYU Alzheimer’s Disease Center Silberstein Alzheimer’s Institute Center for Cognitive.
CSF tau Is it an informative biomarker of AD pathology Chris Clark Alzheimer’s Disease Center University of Pennsylvania.
Mild Cognitive Impairment as a Target for Drug Development Steven H. Ferris, Ph.D. Silberstein Aging and Dementia Research Center New York University School.
Quality Assurance in the clinical laboratory
Alzheimer’s Disease By: Ryan Triplett. Alzheimer’s The deterioration of intellectual capabilities, memory, judgment, and personality to the extent that.
Dementia Research Group MRI, rates of atrophy and Alzheimer’s disease Nick Fox Dementia Research Group Institute of Neurology, UCL Queen Square, London.
Indianapolis Discovery Network for Dementia Forecasting the Future Impact of Early Detection and Management Program for Alzheimer.
Mapping the correlations between CSF Abeta and tau and hippocampal atrophy in 282 ADNI subjects Liana G. Apostolova, Amity E. Green, Kristy S. Hwang, Jonathan.
COST CM1103 Training School Structure-based drug design for diagnosis and treatment of neurological diseases Istanbul, 9-13 Sept 2013 Mirjana Babić, mag.biol.mol.
1 Department for Neuroscience, Croatian Institute for Brain Research, University of Zagreb Medical School, Zagreb, Croatia 2 Laboratory for Molecular Neuropharmacology,
The Worldwide Epidemic of Senile Dementias- Challenges of Pre-Clinical Treatment Evolving Diagnostic Approaches Dimitrios Kapogiannis AAAS 2015 Annual.
Quality Control Lecture 5
Alzheimer’s Disease. Alzheimer's is a the most common form of dementia. Nearly 50-80% of all dementia patients have Alzheimer's. It is a progressive fatal.
Alzheimer’s Disease  Goals  To understand what dementia is  To explore causes, risk factors, symptoms, and treatments of Alzheimer’s Disease  To better.
Evaluation of the Presage™ ST2 ELISA Jun Lu 1, David G. Grenache 1,2 1 ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT 2 Department.
PZP: A novel biomarker for early Alzheimer’s disease ? Diana A.T. Nijholt Department of Neurology Laboratory for Clinical and Cancer Proteomics
Introduction Results Conclusions Acknowledgements Alzheimer’s Disease (AD) is the most common chronic degenerative neurological disease, and there are.
Comparability of methods and analysers Nora Nikolac
conflicts of interest to report.
PharmaCog WP5 / E-ADNI. Enrollment and follow-ups Clinical sites Maximum Minimum PATIENTS EXPECTED.
Recent advances in Trace Element Research in Health and Disease Dubrovnik, Oct 2015 Mirjana Babić Leko, mag.biol.mol Department of Neuroscience Croatian.
Under the supervision of miklós jászberényi
High resolution MRI at 21.1 T of the hippocampus and temporal lobe white matter in the differential classification of Alzheimer’s Disease & Diffuse Lewy.
Alzheimer’s Disease Today and Tomorrow First case reported in 1906 Reported by Alois Alzheimer Patient Augusta D. first treated at 46 years old Paranoia,
L ABORATORY Q UALITY C ONTROL. INTRODUCTION _A major role of the clinical laboratory is the measurement of substances in body fluids or tissues for the.
Biomarkers of Alzheimer’s Disease. Objectively mark Presence of neurodegenerative pathology Change in pathologic activity Purpose.
Bioassay Optimization and Robustness Using Design of Experiments Methodology 2015 NBC, San Francisco June 8, 2015 Kevin Guo.
Introduction The composition of plasma and Cerebrospinal fluid (CSF) are similar with the only major difference between the two being the greatly reduced.
STUDY ON THE LEVELS OF TAU AND β-AMYLOID IN CSF OF PATIENTS WITH MULTIPLE SCLEROSIS Levente Szalárdy MD Department of Neurology University of Szeged Hungary.
Date of download: 6/23/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Pulse Pressure in Relation to Tau-Mediated Neurodegeneration,
Applications of Nanotechnology in Alzheimer’s Disease BioE 494 – Atomic and Molecular Nanotechnology Fall 2007 Deivya Bansal.
INFLUENCE OF FRACTIONAL ANISOTROPY THRESHOLD FOR TRACT BASED DIFFUSION TENSOR ANALYSIS OF UNCINATE FASCICLES IN ALZHEIMER DISEASE Toshiaki Taoka, Toshiaki.
Date of download: 7/7/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Absence of β-Amyloid Deposits After Immunization in.
Date of download: 7/8/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Levels of β-Secretase (BACE1) in Cerebrospinal Fluid.
Date of download: 9/17/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Reduction of SorLA/LR11, a Sorting Protein Limiting.
Myotonic Dystrophy Research: What’s Next
Value of cerebrospinal fluid visinin-like protein-1 (VILIP-1) for prediction of mild cognitive impairment progression to Alzheimer's disease  Mirjana Babić.
Update on the Alzheimer’s Association Quality Control (QC) program
The Alzheimer’s Association QC program for CSF biomarkers
Relationships of zinc and copper CSF levels and ApoE genotype in Alzheimer’s disease  Mirjana Babić Leko1, Jasna Jurasović2#, Matea Nikolac Perković3#,
21st Young Neuroscientist Meeting
The BALTAZAR project: detection and quantification of amyloid peptides, BACE1, TACE and Cathepsin D in the cerebrospinal fluid of patients with AD and.
Fran Borovečki3, Patrick R. Hof4, Nela Pivac2, Goran Šimić1*
Diagnostic potential of cerebrospinal fluid biomarkers in Alzheimer’s disease combined with tau genotypes Mirjana Babić Leko1#, Nanet Willumsen2#, Matea.
Protocol for stereotaxic delivery of tau monomers and oligomers into the rodent brain Lea Langer Horvat*1, Jan Svoboda2, Mirjana Babić Leko1, Terezija.
* Potential use of HP and AMBP in urine for the screening of prostate cancer Sanja Kiprijanovska1, Selim Komina2, Gordana Petrusevska2,
COMBINATION OF CSF PROTEIN BIOMARKERS AND BDNF, IL10 AND IL6 GENOTYPES IN EARLY DIAGNOSIS OF ALZHEIMER’S DISEASE   Mirjana Babić Leko1, Matea Nikolac Perković2,
Annual meeting of the COST ACTION CM1103 Neuropathology and neuropharmacology of monoaminergic system Bordeaux, 8-10 Oct 2014 Pathogenesis and early diagnosis.
NeuroMET and biomarkers
2017 Update on the Alzheimer’s Association
Early diagnosis of mild cognitive impairment and Alzheimer's disease based on salivary lactoferrin  Eva Carro, Fernando Bartolomé, Félix Bermejo-Pareja,
Imaging AD Progression Amyloid Imaging Agents.
Cognitive Disorders and Aging
Neuropathology of Parkinson’s Disease with Dementia (CN)
Early Dementia Distinguishing AD From MCI
Chapter 30 Delirium and Dementia
Reisa Sperling, Elizabeth Mormino, Keith Johnson  Neuron 
Methods Objectives Results Conclusions References
Mechanisms of Neuronal Degeneration in Alzheimer's Disease
Event-related potentials improve diagnosis of Alzheimer’s disease
Likvorski biomarkeri u dijagnostici demencija
Boston Naming Test predicts deterioration of cerebrospinal fluid biomarkers in pre-symptomatic Alzheimer’s disease Charleen Wilder, MA, Kristina Moncrieffe,
Elucidating the Role of TREM2 in Alzheimer’s Disease
Schematic overview of the immuno‐infrared‐sensor, the assay read‐out, and BioFINDER and ESTHER study design Schematic overview of the immuno‐infrared‐sensor,
Columbia University Medical Center
Fig. 1. AD biomarker levels in the cerebrospinal fluid of iNPH, AD, and CN subjects. Box plots of Aβ42 (A), Aβ40 (B), Aβ42/Aβ40 ratio (C), t-tau (D),
CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER.
Presentation transcript:

Proteomic analysis of the cerebrospinal fluid in Alzheimer’s disease Proteomska analiza cerebrospinalne tekućine u Alzheimerovoj bolesti Prof. dr. sc. Goran Šimić, dr. med. Redoviti profesor neuroznanosti i anatomije Full Professor of Neuroscience and Anatomy Zavod za neuroznanost, Hrvatski institut za istraživanje mozga Department of Neuroscience, Croatian Institute for Brain Research Medicinski fakultet Sveučilišta u Zagrebu University of Zagreb Medical School Prvi stručni sastanak Hrvatskog društva za Alzheimerovu bolest i psihijatriju starije životne dobi HLZ Hrvatski liječnički zbor, 11. ožujka Hrvatska zaklada za znanost Projekt br. 09/16 ( ) Croatian Science Foundation

Croatian Science Foundation project Projekt Hrvatske zaklade za znanost

Biološki biljezi AB u CST Biological markers of AD in CSF Three main CSF biomarkers of AD, amyloid β 1-42 (Aβ 1-42 ), total tau (t-tau), and phosphorylated forms of tau proteins (p-tau). Reduction of Aβ 1-42 in CSF of AD patients is explained by Aβ 1-42 aggregation into senile plaques, while increase of t-tau reflects neuronal degeneration, and elevation of p-tau is a consequence of neurofibrillary degeneration and consequent tangles formation in the brain. These CSF biomarkers are altered in early stages of AD, even before the occurrence of the first dementia symptoms. They permit to differentiate patients with prodromal AD (those with mild cognitive impairment, MCI) who often progress to AD, from healthy controls. CSF biomarkers are also used for differentiation of AD from other primary causes of dementia, such as vascular dementia, frontotemporal dementia, and dementia with Lewy bodies. Detection of AD is also critically important in view of the growing number of potential new drugs that may influence the course of the disease in its early phases. However, cut-off levels (isključne vrijednosti) for these CSF biomarkers have not yet been established. Although numerous studies in which diagnostic accuracy of CSF biomarkers was analyzed have been published, an ideal biomarker (with specificity and sensitivity over 85%) could not yet be defined.

Biološki biljezi AB u CST Biological markers of AD in CSF Variability in absolute concentrations of AD biomarkers is high among different centers, laboratories, and studies. Significant differences were noticed even within the same datasets. Causes of variations could be either due to pre-analytical and analytical factors or differences in ELISA kits from various manufacturers. Pre-analytical procedures refer to selection of research participants, CSF sampling and treatment, sample storage (temperature, tube type), and freeze/thaw cycles. Analytical factors that influence results include differences in laboratory procedures among different centers. Variability among ELISA kits from different manufacturers is due to differences in production processes of reagents (e.g., usage of different materials for reagents, preparation of standards, antibody purification, and plate coating). Lot-to-lot variability among assays of the same kit is also an issue. Post-analytical procedures such as curve-fitting type, curve-fitting software, and number of samples analyzed (usually singlets or duplicates) can also affect outcome.

Usporedba ELISA kitova dvaju vodećih proizvo đ ača Comparison of ELISA kits of two major manufacturers As there are insufficient data on comparability of ELISA kits developed by different vendors, we compared the performance of Innogenetics (Gent, Belgium) and Invitrogen (Camarillo, CA, USA) ELISA kits for t-tau and Aβ Analyses were performed in the Laboratory for Developmental Neuropathology (LDN), Croatian Institute for Brain Research, University of Zagreb Medical School, Zagreb, Croatia, and in the Laboratory for Neurobiochemistry (LNB), Department of Laboratory Diagnostics, University Hospital Centre, Zagreb, Croatia.

CSF t-tau levels in AD, MCI and HC subjects measured by Innogenetics and Invitrogen ELISA kit Boxes represent the median, the 25th and the 75th percentiles, bars indicate the range of data distribution. Circles represent outliers (values more than 1.5 box-length from the 75th/25th percentile). The asterisks represent extreme values (value more than three box-length from the 75th/25th percentile). CSF Aβ 1-42 levels in AD patients measured by Innogenetics and Invitrogen ELISA kit Boxes represent the median, the 25th and the 75th percentiles, bars indicate the range of data distribution. Circles represent outliers, the asterisk represents an extreme datapoint. Usporedba ELISA kitova dvaju vodećih proizvo đ ača Comparison of ELISA kits of two major manufacturers

Results of the Passing-Bablok analysis between Innogenetics and Invitrogen ELISA for (A) t-tau and (B) Aβ Note that levels of both t-tau and Aβ 1-42 measured by the Innogenetics kit were significantly higher than those obtained with the Invitrogen kit. Passing-Bablok analysis showed significant differences between Invitrogen and Innogenetics ELISA methods, making it impossible to use them interchangeably. Usporedba ELISA kitova dvaju vodećih proizvo đ ača Comparison of ELISA kits of two major manufacturers

ZAKLJUČAK: Kod multicentričnih istraživanja ne smiju se koristiti komercijalni ELISA kitovi različitih proizvo đ ača! CONCLUSION: Multicenter studies should not use commercial ELISA kits from different manufacturers! Usporedba ELISA kitova dvaju vodećih proizvo đ ača Comparison of ELISA kits of two major manufacturers

Hrvatska zaklada za znanost Projekt br. 09/16 ( ) Croatian Science Foundation Collaborators / Suradnici na projektu Matea Nikolac, Nela Pivac, Dorotea Mück Šeler, Gordana Nedić, Maja Mustapić, Mirjana Babić, Fran Borovečki, Dubravka Švob Štrac, Maja Jazvinšćak Jembrek, Sanja Hajnšek, Ratimir Petrović, Svjetlana Kalanj Bognar, Željka Vukelić, Patrick R. Hof, Milan Radoš, Ninoslav Mimica, Paola Presečki, Danira Bažadona, Nataša Jovanov Milošević, Gabrijela Stanić, Neven Henigsberg